Form 4: Incyte R&D President Exercises, Sells Shares

Incyte Corp's President of R&D, Pablo J. Cagnoni, exercised stock options and subsequently sold the acquired shares on February 19, 2026, under a pre-arranged plan.

Summary

• Pablo J. Cagnoni, President, R&D of Incyte Corp (INCY), reported changes in beneficial ownership.
• On February 19, 2026, Cagnoni acquired 13,093 shares of Common Stock by exercising employee stock options at a price of $61.76 per share.
• On the same date, Cagnoni acquired an additional 5,575 shares of Common Stock by exercising employee stock options at a price of $61.18 per share.
• Immediately following these exercises, Cagnoni disposed of 18,668 shares of Common Stock through a sale at a price of $100.91 per share.
• The total number of shares sold (18,668) matches the total number of shares acquired through option exercises (13,093 + 5,575).
• Following these transactions, Cagnoni directly beneficially owns 234,800 shares of Common Stock, which includes 229,661 shares issuable from unvested restricted stock units and earned performance stock units.
• The transactions were made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a routine executive compensation transaction, pre-planned under Rule 10b5-1, and does not inherently signal a positive or negative shift in company fundamentals.

Positives

• The executive is realizing value from previously granted stock options, indicating personal financial planning and diversification.
• The sale price of $100.91 per share is significantly higher than the exercise prices of $61.76 and $61.18, demonstrating a substantial gain on the exercised options.

Negatives

• Insider selling, even if pre-planned, can sometimes be perceived negatively by the market, though this transaction appears to be a routine exercise-and-sell.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions like this are common for executives managing their equity compensation, often for tax planning, portfolio diversification, or to cover the exercise cost of options. The explicit mention of a Rule 10b5-1 plan indicates these transactions were pre-scheduled, reducing the likelihood they are based on immediate, non-public information.

Comparison to Industry Standards

• The structure of this transaction, involving the exercise of stock options and a subsequent sale of the acquired shares, is a standard practice for executive compensation management across various industries.
• Many executives in biotechnology and pharmaceutical companies, similar to Incyte, utilize Rule 10b5-1 plans to manage their equity holdings in a compliant and pre-planned manner.

Stakeholder Impact

• Shareholders may note the insider sale, but given it's a routine, pre-planned transaction, it is unlikely to significantly alter investor sentiment or company valuation.
• The transaction reflects the executive's personal financial management of their equity compensation.

Next Steps

• Remaining employee stock options will continue to vest according to their schedules, with some becoming exercisable in 37 installments, and others having specific vesting dates.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where an executive exercised stock options and sold the acquired shares. Such transactions are common for managing equity compensation, often for tax obligations or portfolio diversification, and do not typically signal a change in the company's fundamental outlook or warrant a change in investment recommendation based solely on this filing. The pre-planned nature under Rule 10b5-1 further supports a neutral interpretation.

Keywords

Incyte, INCY, Form 4, Insider Transaction, Stock Options, Executive Compensation, Pablo J. Cagnoni, Stock Sale, Rule 10b5-1